| Year |
Citation |
Score |
| 2023 |
Phoolcharoen W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, Pichyangkul S, Taepavarapruk P, Praserthsee W, Malaivijitnond S, Manopwisedjaroen S, Thitithanyanont A, Srisutthisamphan K, Jongkaewwattana A, Tomai M, Fox CB, Taychakhoonavudh S. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant. Vaccine. 41: 2781-2792. PMID 36963999 DOI: 10.1016/j.vaccine.2023.03.027 |
0.309 |
|
| 2023 |
Sagawa ZK, Goman C, Frevol A, Blazevic A, Tennant J, Fisher B, Day T, Jackson S, Lemiale F, Toussaint L, Kalisz I, Jiang J, Ondrejcek L, Mohamath R, Vergara J, ... ... Fox CB, et al. Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults. Nature Communications. 14: 1138. PMID 36878897 DOI: 10.1038/s41467-023-36789-2 |
0.31 |
|
| 2022 |
Milligan EC, Olstad K, Williams CA, Mallory M, Cano P, Cross KA, Munt JE, Garrido C, Lindesmith L, Watanabe J, Usachenko JL, Hopkins L, Immareddy R, Lakshmanappa YS, Elizaldi SR, ... ... Fox CB, et al. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later. Science Translational Medicine. eadd6383. PMID 36454813 DOI: 10.1126/scitranslmed.add6383 |
0.309 |
|
| 2021 |
Abhyankar MM, Mann BJ, Sturek JM, Brovero S, Moreau GB, Sengar A, Richardson CM, Agah S, Pomés A, Kasson PM, Tomai MA, Fox CB, Petri WA. Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant. Npj Vaccines. 6: 137. PMID 34795290 DOI: 10.1038/s41541-021-00399-0 |
0.305 |
|
| 2021 |
Garrido C, Curtis AD, Dennis M, Pathak SH, Gao H, Montefiori D, Tomai M, Fox CB, Kozlowski PA, Scobey T, Munt JE, Mallory ML, Saha PT, Hudgens MG, Lindesmith LC, et al. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology. 6. PMID 34131024 DOI: 10.1126/sciimmunol.abj3684 |
0.306 |
|
| 2021 |
Baldwin SL, Reese VA, Larsen SE, Beebe E, Guderian J, Orr MT, Fox CB, Reed SG, Coler RN. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. Plos One. 16: e0247990. PMID 33705411 DOI: 10.1371/journal.pone.0247990 |
0.315 |
|
| 2018 |
HogenEsch H, O'Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. Npj Vaccines. 3: 51. PMID 30323958 DOI: 10.1038/s41541-018-0089-x |
0.323 |
|
| 2018 |
Singh S, Ramírez-Salazar EG, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, ... ... Fox CB, et al. Control of Heterologous SIV infection by DNA and Protein Co-immunization Regimens Combined with Different Toll-like Receptor-4 (TLR-4) Based Adjuvants in Macaques. Journal of Virology. PMID 29793957 DOI: 10.1128/Jvi.00281-18 |
0.316 |
|
| 2016 |
Barnes V L, Fedor DM, Williams S, Dowling QM, Archer MC, Cloutier S, Parker S, Vedvick TS, Fox CB, Kramer RM. Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge. Aaps Pharmscitech. PMID 28000085 DOI: 10.1208/s12249-016-0688-7 |
0.304 |
|
| 2016 |
Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. Plos One. 11: e0149610. PMID 26901122 DOI: 10.1371/journal.pone.0149610 |
0.315 |
|
| 2016 |
Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Scientific Reports. 6: 19570. PMID 26791076 DOI: 10.1038/srep19570 |
0.305 |
|
| 2015 |
Orr MT, Beebe EA, Hudson T, Argilla D, Huang PD, Reese VA, Fox CB, Reed SG, Coler RN. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine. PMID 26541135 DOI: 10.1016/j.vaccine.2015.10.115 |
0.304 |
|
| 2015 |
O'Hagan DT, Fox CB. New generation adjuvants - From empiricism to rational design. Vaccine. 33: B14-B20. PMID 26022561 DOI: 10.1016/j.vaccine.2015.01.088 |
0.315 |
|
| 2014 |
Noe AR, Espinosa D, Li X, Coelho-Dos-Reis JG, Funakoshi R, Giardina S, Jin H, Retallack DM, Haverstock R, Allen JR, Vedvick TS, Fox CB, Reed SG, Ayala R, Roberts B, et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. Plos One. 9: e107764. PMID 25247295 DOI: 10.1371/Journal.Pone.0107764 |
0.315 |
|
| 2014 |
Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. Plos One. 9: e83884. PMID 24404140 DOI: 10.1371/journal.pone.0083884 |
0.316 |
|
| 2014 |
Orr MT, Kramer RM, Barnes L, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS. Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. Journal of Controlled Release : Official Journal of the Controlled Release Society. 177: 20-6. PMID 24382398 DOI: 10.1016/j.jconrel.2013.12.025 |
0.312 |
|
| 2013 |
Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nature Medicine. 19: 1597-608. PMID 24309663 DOI: 10.1038/nm.3409 |
0.308 |
|
| 2013 |
Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine. 31: 5848-55. PMID 24120675 DOI: 10.1016/j.vaccine.2013.09.069 |
0.302 |
|
| 2013 |
Fox CB. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland. Human Vaccines & Immunotherapeutics. 9: 2007-8. PMID 23787558 DOI: 10.4161/hv.25340 |
0.301 |
|
| 2013 |
Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL. Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza and Other Respiratory Viruses. 7: 815-26. PMID 23122325 DOI: 10.1111/irv.12031 |
0.307 |
|
| 2012 |
Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clinical and Vaccine Immunology : Cvi. 19: 1633-40. PMID 22896687 DOI: 10.1128/CVI.00235-12 |
0.324 |
|
| 2012 |
Fox CB, Wizel B, Reed SG, O’Hagan DT. Enhancing and tailoring the immunogenicity of vaccines with novel adjuvants Development of Novel Vaccines: Skills, Knowledge and Translational Technologies. 45-72. DOI: 10.1007/978-3-7091-0709-6_3 |
0.335 |
|
| 2011 |
Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine. 29: 3284-92. PMID 21349366 DOI: 10.1016/J.Vaccine.2011.02.022 |
0.303 |
|
| 2011 |
Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunological Reviews. 239: 178-96. PMID 21198672 DOI: 10.1111/j.1600-065X.2010.00978.x |
0.326 |
|
| Show low-probability matches. |